Background
==========

Community-acquired pneumonia (CAP) is a common medical condition, with an incidence of 11.6/1000 adults per year.[@b1] It is one of the leading infectious causes of death worldwide[@b2; @b3; @b4] and accounts for substantial use of healthcare resources.[@b5] About 30% of patients with CAP require hospital admission[@b6] and up to one-fifth require intensive care admission.[@b7; @b8; @b9] The estimated costs for treating pneumonia exceeded \$9 billion per year in the mid-1990s in the USA and exceed £441 million per year in the UK.[@b10] [@b11]

The management of CAP is challenging as the outcome depends on multiple factors, such as patient characteristics, care setting, type and virulence of the infective agent, appropriate assessment and nature of healthcare intervention, such as antibiotic administration, and intensive care support, and so on. Thus, clinical determinants of outcomes in CAP have been the subject of considerable research focus over the past few decades.[@b12; @b13; @b14; @b15] Several severity scores have been developed and validated widely, with the aim of guiding the initial site of treatment (eg, home vs hospital; hospital ward vs intensive care unit (ICU)) and appropriate level of intervention, including choice and route of administration of antibiotics.[@b14; @b15; @b16; @b17; @b18; @b19] Better understanding of determinants of patient outcomes in CAP may help clinicians make better clinical decisions in future.

To date, there is no uniform agreement on the optimal severity assessment tool or an agreed definition of the term severe pneumonia.[@b20] Pneumonia Severity Index (PSI) was derived to identify patients with pneumonia who are at low risk for short-term mortality and potential candidates for outpatient care[@b14] and widely used. The British Thoracic Society endorses the use of CURB-65, which is an extensively validated score since the publication of Lim *et al*\'s[@b15] work in stratifying risk of CAP mortality using simple criteria. Its derivative, CRB-65, has the advantage that it is simple and can be implemented without laboratory investigations.[@b21]

Other scores that have since been developed include SMART-COP,[@b18] ADROP,[@b22] CORB,[@b23] SCAP,[@b16] CURSI and CURASI,[@b24] and CURB-age,[@b25] among others. SMART-COP is a tool derived from an Australian study[@b18]; it uses systolic blood pressure, multilobar involvement, albumin levels, respiratory rate adjusted for age, heart rate, confusion, oxygen level adjusted for age and arterial pH to risk stratify for the need for intensive respiratory or vasopressor support.[@b18] The Japanese Respiratory Society proposed the score ADROP to risk stratify, which has been shown to yield similar results as CURB-65. ADROP uses similar parameters as CURB-65, but there are different cut-off values for age (\>70 years for men, \>75 years for women), dehydration (blood urea nitrogen (BUN) \>210 mg/l), respiratory failure (SaO~2~ \<90% or PaO~2~ \<60 mm Hg), orientation disturbance (confusion) and low blood pressure (systolic \<90 mm Hg or diastolic \<60 mm Hg).[@b22] SCAP was developed in Spain, which suggested arterial pH \<7.30, systolic blood pressure \<90 mm Hg, respiratory rate \>30/min, altered mental status, BUN \>30 mg/dl, oxygen arterial pressure \<250 mm Hg, age \>80 years and multilobar/bilateral involvement to predict severe pneumonia.[@b16] CURSI/CURASI and CURB-age are modified versions of CURB-65 and developed in the UK where shock index (pulse rate divided by systolic blood pressure with or without consideration of temperature) is used instead of blood pressure and age in CURSI/CURASI,[@b24] and CURB-age used two cut-off points for urea (\>7 and \>11 mmol/l) and age (65 and 85 years).[@b25]

Several studies have also directly compared different pneumonia severity scales. Man *et al*[@b26] directly compared the PSI, CURB-65 and CRB-65 in a cohort of CAP patients in Hong Kong and found that PSI and CURB-65 has similar performance at predicting 30-day mortality. Capelastegui *et al*[@b27] compared CURB-65 and CRB-65 in a Spanish cohort; they also found similar results using the two scales. Espana *et al*[@b16] tested the SCAP prediction rule in a Spanish cohort and found that it was comparable in predictive value as both the CURB-65 and PSI. Shindo *et al*[@b22] compared the use of ADROP and CURB-65 and found similar results. In the derivation study of SMART-COP, the new score was compared against CURB-65 and PSI and SMART-COP had higher area under the receiver operator curve in predicting need for intensive respiratory or vasopressor support.[@b18]

While PSI and CURB indices were widely validated, newly derived and less well-known CAP severity indices have not been validated in a large sample. We created the International CAP Collaboration Cohort (ICCC) to assess patient-level determinants of prognosis and compare the prognostic accuracy of existing pneumonia risk stratification tools for patients hospitalised with CAP. In this paper, we describe the six prospective CAP cohorts from Asia, Europe and the North America collaborating in ICCC.[@b14] [@b26; @b27; @b28; @b29; @b30] We also provide the rationale, hypotheses and objectives of the study and describe the characteristics of the combined cohort. Finally, we discuss implications and the future direction of research using this data set.

Rationale
---------

While there have been some recent attempts to address existing uncertainties through meta-analysis of severity assessment tools,[@b31] [@b32] somewhat conflicting results arose from the quality of studies included in these meta-analyses. Loke *et al*[@b31] included prospective studies only, and Chalmers *et al*[@b32] included both prospective and retrospective studies. Another limitation of these reviews is that they had to rely on study-level aggregated data, rather than individual patient data. Furthermore, it has also been well recognised that severity measures do not capture specific patient groups. For example, there has been increasing concern with regard to suitability of CURB-65 in both older and younger patients with CAP.[@b33] [@b34] A recent comprehensive review by Singanayagam *et al*[@b20] and a study by Aliberti *et al*[@b35] also highlighted the limitations of current established CAP severity assessment criteria. Therefore, it is important to better understand the determinants and outcomes of CAP in a heterogeneous patient population to improve the identification of patients with higher risk of poor outcomes, taking into account of other important factors, such as ethnicity, and healthcare systems. The rationale of ICCC is to address the specific objectives based on the hypotheses set out below by creating a CAP cohort with large sample size with adequate power. This paper aims to describe this ICCC cohort, which will test the hypotheses and describe the pooled outcomes across studies of different world regions.

Hypotheses and objectives
-------------------------

The hypotheses are as follows:Different severity assessment tools for CAP have different advantages and disadvantages.It is possible to identify patients with CAP who have been initially classified as having non-severe CAP by one scoring system but who are at risk of death.It is possible to apply more than one scoring system sequentially to better identify CAP patients at high risk of mortality.There are patient characteristics, which can be identified, which is associated with increased risk of death in specific patient groups.

The main objectives of the ICCC, therefore, are to:compare the accuracy (sensitivity, specificity, predictive values and likelihood ratios) and discrimination (receiver operating characteristics analyses) of existing severity tools in predicting 30-day mortality and/or ICU admission;explore the characteristics of patients with pneumonia with poor outcome despite who scored non-severe at initial assessment to identify relatively high-risk group of patients;examine whether using sequential assessment with two separate rules (eg, one deployed as a triage test in primary care or emergency department, followed by a more specific test to guide inpatient management) would improve predictive ability;evaluate risk factors for prognosis and compare the performance of existing severity rules in distinct patient subgroups, for example, Nursing Home Acquired Pneumonia, in those with chronic obstructive pulmonary disease (COPD) and people who are immunocompromised.

Methods
=======

Our patient population was derived from previously reported prospective CAP cohorts that were included in a meta-analysis comparing the PSI and CURB-65.[@b31] The published CAP literature was reviewed as described in Loke *et al*,[@b31] and the largest cohorts (n\>1000) meeting the required standard of the review were invited to participate.[@b14] [@b26; @b27; @b28; @b29; @b30] Each individual studies had prior respective institutional research ethics approval for their original data collection, and ICCC study was approved by the Faculty of Medicine and Health Sciences Research Ethics Committee, University of East Anglia, UK (Ref, 2011/2012-29).

The main inclusion criteria at individual patient level were adults with diagnosis of pneumonia based on the combination of clinical symptoms and signs of pneumonia (cough, sputum and fever) and radiological findings of an opacity (or opacities) on chest radiograph consistent with pneumonia. The coordinating centre (CC) from the UK prepared a standardised data sheet, and it was distributed to all collaborating centres for data entry. The variables listed in the [appendix 1](#app1){ref-type="app"} were requested to all centres. The data were based on all the variables needed to calculate the PSI score as well as the CURB-65 score, which also cover most of the variables included in less well-known criteria. Therefore, those who only reported CURB indices were not considered for inclusion into the ICCC. We identified five research groups who had relevant data on six cohorts, and all five groups replied positively to the request. Additional baseline information collected included patient comorbidities, patient residence, antibiotic treatment they received and the route of administration of antibiotics. Outcomes such as admission to ICU with or without ventilation and high dependency unit (HDU) were collected along with the main outcome of 30-day mortality.

Anonymised patient data were entered by the participating centres and returned to the CC. Data were checked and compiled by the research team at CC. Data standardisation (eg, converting to same SI units) and quality checking were centrally conducted. First, all the data were combined into a single data file with the same coding and units for each variable. Most dichotomous variables values were coded as numbers (0=no, 1=yes) and blanks for missing values. In particular, urea values were converted to BUN by multiplying by a factor of 2.8. For each variable, the values were checked for errors by considering the maximum and minimum values or values that are beyond the expected/plausible range. Finally, some variables were combined to generate new variables, including any ICU variable (ICU with ventilation and ICU without ventilation combined) and any ICU/HDU variable (any ICU and HDU admission combined).

Analytical approach
-------------------

Data are presented descriptively for individual cohorts as well as the ICCC (combined cohort) for the purposes of the current report. We pooled the cohorts by simple aggregation of individual patient data rather than using any form of weighting or meta-analytic techniques to combine the study and explore the heterogeneity. We present median (IQR) values for non-normally distributed data and mean (SD) for normally distributed continuous data and numbers (percentages) for categorical data. We analysed the data using STATA V.10.0 (2009, StataCorp).

At present, we have simply pooled the data and describe the cohort in this rationale paper, but expect to use meta-analytic techniques and individual patient data approaches to better explore between cohort heterogeneity, such as ethnicity and healthcare setting, and how it may relate to outcomes. Furthermore, we should be able to explore more general issues such as how best to deal with missing data in large clinical samples (ie, complete case, dummy variables for missing data, imputation).

Overview of study designs and methods
-------------------------------------

Overall, five research teams responsible for assembling six potentially eligible cohorts were invited to participate. In all six cohorts, CAP was defined based on the presence of clinical symptoms and signs of pneumonia, and the presence of radiographic pulmonary opacity/opacities consistent with CAP, as interpreted by either the treating physician or by a staff radiologist. Patients recruited were those with CAP first presenting to an outpatient department (cohort 3) or the emergency departments (all other cohorts) (see [table 1](#tbl1){ref-type="table"}). In general, all cohorts used similar inclusion criteria with similar reliable methods to diagnose pneumonia combing both clinical evidence and radiological features of pneumonia. The ascertainment of survival at 30 days varied from telephone interviews to record linkage using administrative healthcare databases. Four of six cohorts recruited participants from multiple centres, while two (Hong Kong and Spain) involved only a single centre.

###### 

Overview of study designs and methods

             Year of establishment/location                                                                                                             Type of healthcare setting                                                                                            Inclusion/exclusion criteria                                                                                                                                                                                                                                                                                                             CAP definition                                                                                                                                                                                                  Outcome ascertainment methods
  ---------- ------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cohort 1   GenIMS cohort, November 2001--2003, 28 hospitals in southwestern Pennsylvania, Connecticut, southern Michigan and western Tennessee, USA   Hospital emergency departments                                                                                        Age \>18 years with CAP. Excluded were those transferred from another hospital, discharged from hospital within previous 10 days, receiving chronic mechanical ventilation, with cystic fibrosis, active tuberculosis, admitted for palliative care, previous enrolled in GenIMS study, incarcerated or pregnant                         Clinical and radiological diagnosis (one or more symptoms suggestive of pneumonia and radiographic evidence of pneumonia within 24 h of presentation)                                                           Data were collected by structured patient or proxy interviews, bedside assessment, medical records abstraction and telephone call and National Death Index search for those discharged
  Cohort 2   January 2001--December 2007, a single hospital in Galdakao, Spain                                                                          Hospital emergency department                                                                                         Age \>18 years with CAP. Excluded were those who were HIV positive, immunosuppressed or had been hospitalised for previous 14 days                                                                                                                                                                                                       New pulmonary infiltrate on chest radiograph and symptoms consistent with pneumonia, including cough, dyspnoea, fever and/or pleuritic chest pain                                                               Data were recorded from medical records and follow-up was conducted either by medical examination at hospital or by telephone call
  Cohort 3   PORT cohort, October 1991--March 1994, five medical institutions in Pittsburgh and Boston, USA and Halifax, Nova Scotia, Canada            Outpatients and inpatients                                                                                            Age \>18 years with CAP, informed consent for baseline and follow-up interviews. Excluded were those discharged from an acute care hospital within 10 days before presentation with pneumonia or those who are HIV-positive                                                                                                              One or more symptoms of suggestive of pneumonia with radiographic evidence of pneumonia.Screened ∼13 000                                                                                                        Data collected by patient or proxy interview by clinical research assistants
  Cohort 4   November 2000--November 2002, at all six sites in Edmonton, Alberta, Canada (population-based)                                             Six emergency departments and affiliated hospitals: two tertiary, two secondary and two smaller community hospitals   Patients with CAP including nursing home patients. Excluded were those directly admitted to intensive care units, hospitalised previous 10--14 days, tuberculosis, cystic fibrosis, pregnant, nursing mothers and immunosuppression, including HIV infection. Patients treated according to a previously validated clinical pathway      Two or more symptoms of pneumonia (cough, pleuritic chest pain, shortness of breath, temperature \>38°C, crackles or bronchial breathing) and radiographic evidence as interpreted by the treating physicians   Prospective data collection including telephone interviews, ward visits, chart reviews and 5-year follow-up using administrative linked healthcare databases
  Cohort 5   January 2004--June 2005, a single hospital in Hong Kong                                                                                    Hospital emergency department                                                                                         Age \>17 years with CAP. Excluded were immunosuppressed, pulmonary tuberculosis and patients admitted to hospital within the previous 14 days                                                                                                                                                                                            Symptoms of acute infection and acute infiltrate on a chest radiograph in a patient not hospitalised for more than 14 days before onset of symptoms                                                             Data recorded by standard questionnaire by a trained research nurse
  Cohort 6   ED-CAP cohort, January 2001--December 2001, 32 hospitals in Connecticut and Pennsylvania, USA                                              Hospital emergency departments                                                                                        Age \>18 years with CAP. Excluded were patients who had hospital-acquired pneumonia, cystic fibrosis, pulmonary tuberculosis or were immunosuppressed, incarcerated, homeless, pregnant, previously enrolled or had psychosocial conditions or substance abuse problems that were incompatible with treatment, enrolment and follow-up   Clinical diagnosis of pneumonia and new pulmonary infiltrate identified on radiography                                                                                                                          Research staff collected data with structured review of patient\'s medical records and telephone interviews

CAP, community-acquired pneumonia.

Baseline patient characteristics
--------------------------------

[Table 2](#tbl2){ref-type="table"} shows the patient-related sample characteristics. The median ages of cohorts ranged between 59 and 76 years at the time of enrolment (median age in this pooled data set is 71 years; IQR 52--80 years), of which 54% were men. Data on race and ethnicity were available in four cohorts. Data on smoking and alcohol use were available for 54% and 74%, respectively, of the patients. Only 1% of the ICCC patient population has missing data for whether they were admitted from nursing home facility or elsewhere.

###### 

Patient-related characteristics of individual collaborating cohorts and the combined cohort (ICCC)

  Variables                                             Cohort 1 (n=1847)   Cohort 2 (n=2110)   Cohort 3 (n=2287)   Cohort 4 (n=3415)   Cohort 5 (n=1014)   Cohort 6 (n=3201)   ICCC (n=13 874)
  ----------------------------------------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -----------------
  Age (years)                                           65 (47--83)         71 (54--87)         56 (35--77)         69 (51--87)         74 (62--86)         63 (43--83)         65 (46--85)
  Sex                                                                                                                                                                           
   Men                                                  950 (51.4%)         1376 (65.2%)        1144 (50.0%)        1803 (52.8%)        645 (63.6%)         1554 (48.5%)        7472 (53.9%)
   Women                                                897 (48.6%)         734 (34.8%)         1143 (50.0%)        1612 (47.2%)        369 (36.4%)         1647 (51.4%)        6402 (46.1%)
  Ethnicity                                                                                                                                                                     
   White                                                1456 (78.8%)        --                  1949 (85.2%)        0 (0%)              0 (0%)              2791 (87.9%)        6196 (44.7%)
   Black                                                305 (16.5%)         --                  292 (12.7%)         0 (0%)              0 (0%)              309 (9.1%)          906 (6.5%)
   Asian                                                5 (0%)              --                  16 (0.7%)           0 (0%)              1014 (100%)         81 (2.4%)           1116 (8.0%)
   Hispanic                                             58 (2.7%)           --                  0 (0%)              0 (0%)              0 (0%)              8 (0.2%)            66 (0.5%)
   Non-aboriginal                                       0 (0%)              --                  0 (0%)              3293 (96.4%)        0 (0%)              0 (0%)              3293 (23.7%)
   Aboriginal                                           0 (0%)              --                  0 (0%)              122 (3.6%)          0 (0%)              0 (0%)              122 (0.9%)
   Other                                                23 (1.2%)           --                  30 (1.3%)           0 (0%)              0 (0%)              11 (0.3%)           64 (0.5%)
   Missing/NA                                           0 (0%)              2110 (100%)         0 (0%)              0 (0%)              0 (0%)              1 (\<0.1%)          2111 (15.2%)
  Smoking status[\*](#table-fn1){ref-type="table-fn"}                                                                                                                           
   Non-smoker                                           92 (5.0%)           246 (11.7%)         1664 (72.8%)        1454 (42.6%)        885 (87.3%)         --                  4340 (31.3%)
   Ex-smoker                                            --                  168 (8.0%)          --                  939 (27.5%)         --                  --                  1107 (8.0%)
   Smoker                                               --                  89 (4.2%)           --                  1023 (29.9%)        --                  --                  1112 (8.0%)
   Smoking history                                      232 (12.6%)         --                  604 (26.4%)         --                  129 (12.7%)         --                  965 (7.0%)
   Missing/NA                                           1523 (82.5%)        1607 (76.2%)        19 (0.8%)           0 (0%)              0 (0%)              3201 (100%)         6350 (45.8%)
  Alcohol use                                                                                                                                                                   
   Yes                                                  1186 (64.2%)        107 (5.1%)          357 (15.6%)         245 (7.2%)          9 (0.9%)            --                  1904 (13.7%)
   No                                                   642 (34.8%)         1983 (94.0%)        1562 (68.3%)        3170 (92.8%)        999 (98.5%)         --                  8356 (60.2%)
   Missing/NA                                           19 (1.0%)           20 (0.9%)           368 (16.1%)         0 (0%)              6 (0.6%)            3201 (100%)         3614 (26.0%)
  Nursing home                                                                                                                                                                  
   Yes                                                  81 (4.3%)           173 (8.2%)          195 (8.5%)          637 (21.9%)         0 (0%)              130 (4.1%)          1216 (8.8%)
   No                                                   1628 (88.1%)        1937 (91.8%)        2092 (91.5%)        2778 (78.1%)        1014 (100%)         3071 (95.9%)        12 520 (90.2%)
   Missing                                              138 (7.5%)          0 (0%)              0 (0%)              0 (0%)              0 (0%)              0 (%)               138 (1.0%)

Values presented are median (IQR) for normally distributed and non-normally distributed continuous data (other continuous variables) and number (%) for all categorical data. Percentages may not sum to 100% due to rounding.

Some cohorts (cohorts 1, 3 and 5 recorded smoking history without differentiating between ex- and current smokers).

ICCC, International Community-Acquired Pneumonia (CAP) Collaboration Cohort; NA, not available.

[Table 3](#tbl3){ref-type="table"} shows the prevalence of comorbid conditions. The most commonly captured comorbid conditions were COPD, coronary artery disease and stroke/cerebrovascular disease. Five cohorts have available data on background dementia (total n=832 of 12 021, 0.07%), and all have information on presence or absence of malignant disease (total n=912 of 13 744, 0.07%).

###### 

Distribution of selected comorbid conditions in individual collaborating cohorts and the combined cohort

  Comorbidities             Cohort 1      Cohort 2      Cohort 3      Cohort 4      Cohort 5      Cohort 6      ICCC
  ------------------------- ------------- ------------- ------------- ------------- ------------- ------------- ---------------
  COPD                                                                                                          
   Yes                      --            569 (27.0)    588 (25.7)    638 (18.7)    10 (1.0)      1034 (32.3)   2839 (20.5)
   No                       --            1541 (73.0)   1687 (73.8)   2777 (81.3)   1004 (99.0)   2167 (67.7)   9176 (66.1)
   Missing/NA               1847 (100)    0 (0)         12 (0.5)      0 (0)         0 (0)         0 (0)         1859 (13.4)
  Asthma                                                                                                        
   Yes                      --            --            --            440 (12.9)    1 (0.01)      --            441 (3.2)
   No                       --            --            --            2975 (87.1)   1013 (99.9)   --            3988 (28.7)
   Missing/NA               1847 (100)    2110 (100)    2287 (100)    0 (0)         0 (0)         3201 (100)    9445 (68.1)
  Pleural effusion                                                                                              
   Yes                      201 (10.9)    219 (10.4)    204 (8.9)     745 (21.8)    112 (11.0)    461 (14.4)    1942 (14.0)
   No                       1523 (82.5)   1891 (89.6)   1976 (86.4)   2670 (78.2)   902 (89.0)    2715 (84.8)   11 677 (84.2)
   Missing/NA               123 (6.7)     0 (0)         107 (4.7)     0 (0)         0 (0)         25 (0.8)      255 (1.8)
  Heart failure                                                                                                 
   Yes                      294 (15.9)    163 (7.7)     253 (11.1)    727 (21.3)    121 (11.9)    427 (13.3)    1985 (14.3)
   No                       1429 (77.4)   1947 (92.3)   2030 (88.8)   2688 (78.7)   893 (88.1)    2774 (86.7)   11 761 (84.8)
   Missing/NA               124 (6.7)     0 (0)         4 (0.2)       0 (0)         0 (0)         0 (0)         128 (0.9)
  Coronary artery disease                                                                                       
   Yes                      --            215 (10.2)    406 (17.8)    910 (26.6)    --            667 (20.8)    2198 (15.8)
   No                       --            1895 (89.8)   1880 (82.2)   2505 (73.4)   --            2534 (79.2)   8814 (63.5)
   Missing/NA               1847 (100)    0 (0)         1 (\<0.1)     0 (0)         1014 (100)    0 (0)         2862 (20.6)
  Cerebrovascular disease                                                                                       
   Yes                      150 (8.1)     200 (9.5)     210 (9.2)     306 (9.0)     143 (14.1)    267 (8.3)     1276 (9.2)
   No                       1574 (85.2)   1910 (90.5)   2076 (90.8)   3109 (91.0)   871 (85.9)    2934 (91.7)   12 474 (89.9)
   Missing                  123 (6.7)     0 (0)         1 (\<0.1)     0 (0)         0 (0)         0 (0)         124 (0.9)
  Liver disease                                                                                                 
   Yes                      34 (1.8)      76 (3.6)      33 (1.4)      117 (3.4)     17 (1.7)      28 (0.9)      305 (2.2)
   No                       1690 (91.5)   2034 (96.4)   2251 (98.6)   3298 (96.6)   997 (98.3)    3173 (99.1)   13 443 (96.9)
   Missing                  123 (6.7)     0 (0)         3 (0)         0 (0)         0 (0)         0 (0)         126 (0.9)
  Renal disease                                                                                                 
   Yes                      89 (4.8)      160 (7.6)     153 (6.7)     490 (14.3)    106 (10.5)    108 (3.4)     1106 (8.0)
   No                       1635 (88.5)   1950 (92.4)   2131 (93.2)   2925 (85.7)   908 (89.5)    3093 (96.6)   12 642 (91.1)
   Missing                  123 (6.7)     0 (0)         3 (0.1)       0 (0)         0 (0)         0 (0)         126 (0.9)
  Cancer                                                                                                        
   Yes                      87 (4.7)      131 (6.2)     109 (4.8)     499 (14.6)    1 (0.1)       85 (2.7)      912 (6.6)
   No                       1637 (88.6)   1979 (93.8)   2171 (94.9)   2916 (85.4)   1013 (99.9)   3116 (97.3)   12 832 (92.5)
   Missing                  123 (6.7)     0 (0)         7 (0.3)       0 (0)         0 (0)         0 (0)         130 (0.9)
  Diabetes                                                                                                      
   Yes                      --            309 (14.6)    235 (10.3)    190 (5.6)     --            625 (19.5)    1359 (9.8)
   No                       --            1801 (85.4)   2052 (89.7)   3225 (94.4)   --            2576 (80.5)   9654 (69.6)
   Missing/NA               1847 (100)    0 (0)         0 (0)         0 (0)         1014 (100)    0 (0)         2861 (20.6)
  Dementia                                                                                                      
   Yes                      --            276 (13.1)    141 (6.2)     265 (7.8)     22 (2.2)      128 (4.0)     832 (6.0)
   No                       --            1834 (86.9)   2141 (93.6)   3150 (92.2)   992 (97.8)    3072 (96.0)   11 189 (80.6)
   Missing/NA               1847 (100)    0 (0)         5 (0.2)       0 (0)         0 (0)         1 (\<0.1)     1853 (13.4)
  Seizure                                                                                                       
   Yes                      --            --            91 (4.0)      151 (4.4)     2 (0.2)       --            244 (1.8)
   No                       --            --            2196 (96.0)   3264 (95.6)   1012 (99.8)   --            6272 (45.9)
   Missing/NA               1847 (100)    2110 (100)    0 (0)         0 (0)         0 (0)         3201 (100)    7158 (52.3)

Values presented are number (%). Percentages may not sum to 100% due to rounding.

COPD, chronic obstructive pulmonary disease; ICCC, International Community-Acquired Pneumonia (CAP) Collaboration Cohort; NA, not available.

[Table 4](#tbl4){ref-type="table"} shows clinical and laboratory characteristics. There were no material differences in key clinical characteristics among cohorts, except for prevalence of confusion, which was relatively lower in cohort 1, and mean systolic blood pressure that was notably higher in cohort 5 where the median age of the cohort was relatively higher than other cohorts. All six studies used the PSI for risk stratification, and two cohorts (cohorts 2 and 5) also used the CURB-65. Overall, as defined within each cohort, 6159 (44%) patients had severe pneumonia by PSI class IV/V.

###### 

Selected clinical and laboratory characteristics of individual collaborating cohorts and the combined cohort

  Variable                        Cohort 1 (n=1847)   Cohort 2 (n=2110)           Cohort 3 (n=2287)           Cohort 4 (n=3415)            Cohort 5 (n=1014)            Cohort 6 (n=3201)           ICCC (n=13 874)
  ------------------------------- ------------------- --------------------------- --------------------------- ---------------------------- ---------------------------- --------------------------- -----------------
  Confusion                                                                                                                                                                                         
   Yes                            57 (3.1)            269 (12.7)                  238 (10.4)                  701 (20.5)                   92 (9.1)                     121 (3.8)                   1478 (10.7)
   No                             1689 (91.4)         1841 (87.3)                 2047 (89.5)                 2714 (79.5)                  922 (90.9)                   3080 (96.2)                 12 293 (88.6)
   Missing                        101 (5.5)           0 (0)                       2 (\<0.1)                   0 (0)                        0 (0)                        0 (0)                       103 (0.7)
  BUN                                                                                                                                                                                               
   Continuous                     --                  28 (12--43) (n=2110)        23 (5--41) (n=1500)         26 (5--47) (n=2930)          23 (7--39) (n=1014)          21 (7--36) (n=2518)         --
   Categorical                                                                                                                                                                                      
    ≥30 (mg/dl)                   264 (14.3)          660 (31.3)                  326 (14.3)                  748 (21.8)                   198 (19.5)                   430 (13.4)                  2626 (18.8)
    \<30 (mg/dl)                  1456 (78.8)         1450 (68.7)                 1174 (51.3)                 2185 (64.1)                  816 (80.5)                   2088 (65.2)                 9169 (66.1)
    Missing                       127 (6.9)           0 (0)                       787 (34.4)                  482 (14.1)                   0 (0)                        683 (21.3)                  2079 (15.0)
   Urea (mmol/l)                  --                  9.9 (4.4--15.5) (n=2110)    8.2 (1.8--14.6) (n=1500)    9.3 (1.9--16.7) (n=2930)     8.3 (2.4--14.1) (n=1014)     7.7 (2.4--12.8) (n=2518)    --
  Respiratory rate/min                                                                                                                                                                              
   Continuous                     --                  23 (16--30) (n=2110)        24 (15--33) (n=1805)        26 (18--34) (n=3294)         24 (19--30) (n=1014)         23 (17--28) (n=3201)        --
   Respiratory rate high          24 (20--28)         --                          --                          --                           --                           --                          --
   Respiratory rate low           20 (18--20)         --                          --                          --                           --                           --                          --
   Categorical                                                                                                                                                                                      
    \>30 (/min)                   0 ()                275 (13.0)                  269 (11.8)                  787 (23.1)                   125 (12.3)                   287 (9.0)                   1743 (12.6)
    ≤30 (/min)                    0 (0)               1835 (87.0)                 1525 (67.0)                 2504 (73.4)                  889 (87.7)                   2896 (90.5)                 9649 (69.6)
    Missing/NA                    1847 (100)          0 (0)                       482 (21.2)                  121 (3.5)                    0 (0)                        18 (0.6)                    2468 (17.8)
  Systolic BP (mm Hg)                                                                                                                                                                               
   Continuous                     --                  132 (27) (n=2106)           134 (28) (n=2020)           134 (27) (n=3371)            145 (28) (n=1014)            138 (26) (n=3192)           -- (n=13 874)
   Categorical                                                                                                                                                                                      
    ≥90 mm Hg                     1650 (89.3)         1999 (94.9)                 1971 (86.2)                 3282 (96.2)                  1002 (98.8)                  3140 (98.1)                 13 044 (94.1)
    \<90 mm Hg                    68 (3.7)            107 (5.1)                   49 (2.1)                    89 (2.6)                     12 (1.2)                     52 (1.6)                    377 (2.7)
    Missing                       129 (7.0)           0 (0)                       267 (11.7)                  41 (1.2)                     0 (0)                        9 (0.3)                     446 (3.2)
  Diastolic BP (mm Hg)            --                  72 (15) (n=2074)            76 (15) (n=1936)            75 (16) (n=3365)             73 (16) (n=1014)             75 (15) (n=3156)            --
   Diastolic BP high              77 (62--92)         --                          --                          --                           --                           --                          --
   Diastolic BP low               63 (49--79)         --                          --                          --                           --                           --                          --
  Temperature (°C)                --                  37.5 (1.0) (n=2110)         37.6 (1.1) (n=2018)         37.3 (1.2) (n=3369)          37.9 (1.1) (n=1014)          37.6 (1.1) (n=3168)         --
  Heart rate (beats per minute)   --                  98 (21) (n=2110)            99 (20) (n=1971)            101 (22) (n=3401)            102 (20) (n=1014)            99 (20) (n=3197)            --
   Heart rate high                104 (84--125)       --                          --                          --                           --                           --                          --
   Heart rate low                 85 (68--102)        --                          --                          --                           --                           --                          --
  PaO~2~ (mm Hg)                  --                  61 (47--75) (n=2050)        70 (41--100) (n=959)        68 (37--100) (n=2278)        93 (64--122) (n=1013)        74 (37--112) (n=593)        --
  pH                              --                  7.45 (7.38--751) (n=2052)   7.45 (7.37--7.51) (n=959)   7.43 (7.33--7.50) (n=2248)   7.41 (7.32--7.49) (n=1014)   7.42 (7.35--7.49) (n=593)   --
  Glucose (mg/dl)                 --                  151 (81--220) (n=2108)      141 (72--209) (n=1459)      142 (76--209) (n=2987)       137 (84--191) (n=1014)       123 (74--214) (n=2510)      --
   Glucose high                   147 (67--227)       --                          --                          --                           --                           --                          --
   Glucose low                    135 (75--196)       --                          --                          --                           --                           --                          --
  Sodium (mmol/l)                 --                  136 (131--141) (n=2110)     137 (132--142) (n=1495)     137 (132--143) (n=3272)      136 (131--140) (n=1013)      137 (133--141) (n=2524)     --
   Sodium high                    137 (132--142)      --                          --                          --                           --                           --                          --
   Sodium low                     137 (132--142)      --                          --                          --                           --                           --                          --

Values presented are mean (SD) for normally distributed (systolic BP, diastolic BP, temperature and heart rate) and median (IQR) for non-normally distributed continuous data (other continuous variables) and number (%) for all categorical data. Percentages may not sum to 100% due to rounding.

BP, blood pressure; BUN, blood urea nitrogen; ICCC, International Community-Acquired Pneumonia (CAP) Collaboration Cohort; NA, not available.

All cohorts had complete data on 30-day mortality outcome but recorded ICU and HDU admission in various format/coding. Generally, all cohorts have complete data for ICU and/or HDU outcome (only 1 with missing data). The 30-day mortality ranged between 4% and 11%, with an overall ICCC 30-day mortality of 8% (n=1036). Admission to intensive care or HDU was also 8% (1059).

Missing data and data that were not recorded
--------------------------------------------

Overall, across all cohorts, there were 12.2% of data that were requested from each cohort that were not recorded and maximum of 6% of data were missing (see [appendix 2](#app2){ref-type="app"}).

Discussion
==========

The ICCC is a multicentre/multiethnic cohort where all collaborating groups defined pneumonia based on clinical features and the presence of CXR evidence of pneumonia. The major strengths of ICCC are prospective study design, inclusion of CAP patients spanning across wide age range, ethnicity, different healthcare settings and large sample size. Potential areas of improvement in assessment of CAP might be identification of at-risk patients with pneumonia who have been initially assessed as non-severe CAP. With large sample size, ICCC may provide an opportunity to identify characteristics of such individuals. Based on this work, risk assessment may be applied at more than one point in time in order to observe temporal trends in recovery or deterioration in future CAP research and clinical practice.

Furthermore, despite there being some degree of missing data, the large sample size of ICCC enables us to examine the CAP outcome in patient populations with specific characteristics of interest. Examples of such groups include those with COPD and cancer and patients admitted from nursing homes. Another important aspect in estimating prognosis in patients with CAP is with regard to older people whose mortality outcome is substantially higher. The ICCC provides a large prospective cohort of older people aged 65 years and older and subset of extremely old patients (aged 85+ years). The usefulness of different assessment scores and impact of co-existing comorbidities can be further examined to enhance the understanding of prognosis in this growing patient population due to current and expected demographics.

In addition, there have been studies that evaluate mortality risk scores in specific patient populations with CAP. The elderly represent a distinct population group, and the SOAR score has been developed specifically to predict mortality.[@b36] The MELD-CAP score has been show to outperform CURB-65 and PSI in patients with cirrhosis.[@b37] For patients admitted to the ICUs, the PIRO score has been developed.[@b19] There have also been other studies, which look at predictive value of pneumonia severity scores in other populations, including patients with H1N1 infection,[@b38] HIV infection[@b39] and chronic kidney disease.[@b40] Therefore, ICCC also provides a large cohort, which may be able to address the value of different pneumonia severity scores in specific populations.

Our study has limitations. There were multiple observers and data collections across several centres. However, all cohorts followed the strict criteria in data collection as described in [table 1](#tbl1){ref-type="table"}. Furthermore, the data collected were objective measures such as age and urea level, thereby ruling out potential observer bias. The process of care between hospitals may be variable. There may be a variation in clinical management between different hospitals and in different healthcare setting between the various countries such as there may be important variations in antibiotic use, patterns of infective micro-organisms, care protocols and treatment guidelines. Other limitations to consider are biomarkers, healthcare provider and site characteristics. The patients were enrolled into the study at different time periods. However, this presents an opportunity to compare and contrast different healthcare systems to better understand the variation in healthcare setting and outcomes. Since all six studies used the PSI for risk stratification, this can have implications, for example, patients who scored non-severe at initial assessment (low PSI) but might have had worse outcome are under-represented if such patients were sent home. This could contribute to attenuation of estimates in low PSI group. Nevertheless, it is possible that these patients would have presented again to the medical centre if/when deterioration occurred. Cohorts that only had data on CURB-related variables and cohorts with smaller sample sizes were not included in the ICCC, and this may introduce some degree of selection bias. Nevertheless, this should not have any effect on the internal relationship between the predictors and outcomes of interest.

In summary, the ICCC as described in this report will be able to provide better understanding of determinants of outcomes in CAP. Examples of such development include comparison of commonly and less commonly known CAP severity scoring systems and identification of characteristics of CAP patients with poor outcome (30-day mortality) despite non-severe status of severity score. In view of the large sample size, the ICCC cohort will be able to provide the determinants of outcomes in patient groups with specific conditions such as cardiovascular and respiratory diseases taking into account case mix and individual prognostic indicators. The ICCC cohort will be of benefit to the CAP research community and help define a future agenda for research, as well as helping clinicians make better clinical decisions for patients with CAP.
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Variables requested from each collaborating cohort
==================================================

-   Age (continuous)

-   Gender (male/female)

-   BMI

-   Race

-   Smoking

-   Alcohol

-   Illicit drug use

-   Altered mental status (yes/no)

-   Altered mental status (abbreviated mental test score if measured as continuous)

-   Urea or BUN levels (continuous)

-   BUN category (as per PSI using cut-off point of 30; ≤30 vs \>30)

-   Respiratory rate (continuous)

-   Respiratory rate (categorical as per PSI using cut-off point of 30; \<30 vs ≥30)

-   Systolic blood pressure (continuous)

-   Systolic blood pressure (categorical as per PSI using cut-off point of 90; \<90 vs ≥90)

-   Diastolic blood pressure (continuous) (for CURB-65/CRB calculation)

-   Pneumonia Severity Index score (sum)

Other parameters in Pneumonia Severity Index
============================================

-   Residence (categorical data with coding)

-   Nursing home residence (yes/no)

-   Renal disease (yes/no)

-   Liver disease (yes/no)

-   CHF (yes/no)

-   Cerebrovascular disease (yes/no)

-   Neoplasia (yes/no)

-   Temperature (continuous)

-   Temperature (categorical as per PSI; \<35 or ≥40 vs 35--40)

-   Heart rate (continuous)

-   Heart rate (categorical as per PSI; \<125 vs ≥125)

-   pH (continuous)

-   pH (categorical as per PSI; \<7.35 vs ≥7.35)

-   PO2 (continuous)

-   PO2 (categorical as per PSI; \<60 vs ≥60)

-   Saturation (continuous)

-   Saturation (categorical as per PSI using cut-off point of 90; \<90 vs ≥90)

-   Sodium (Na) (continuous)

-   Sodium (categorical as per PSI using cut-off point of 130; \<130 vs ≥130)

-   Haematocrit (continuous)

-   Haematocrit (categorical as per PSI using cut-off point of 30; \<30 vs ≥30)

-   Glucose (continuous)

-   Glucose (categorical as per PSI using cut-off point of 250; ≤250 vs \>250)

-   Pleural effusion (yes/no)

-   Comorbidities (others)

-   Antibiotic use (in text)

-   Route (IV/oral)

-   Whether they completed the study (lost to follow-up) (yes/no)

-   Whether they died during the 30-day follow-up (yes/no)

-   Whether they died during admission (in hospital death) (yes/no)

-   Date of death (dd/mm/yyyy format)

-   Death within 30 days (yes/no)

-   Whether they were admitted to intensive care unit (for ventilation) (yes/no)

-   Whether they were admitted to high dependency unit (yes/no)

-   Whether they were admitted to ICU without ventilatory support (yes/no)

  Variable           Cohort 1 (n=1847)   Cohort 2 (n=2110)   Cohort 3 (n=2287)   Cohort 4 (n=3415)   Cohort 5 (n=1014)   Cohort 6 (n=3201)                           
  ------------------ ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- --- ------ --- ---- --- ------
  Age                N                   0                   N                   0                   N                   0                   N   0      N   0    N   0
  Sex                N                   0                   N                   0                   N                   0                   N   0      N   0    N   0
  Ethnicity          N                   0                   Y                   NA                  N                   0                   N   0      N   0    N   1
  Smoking            N                   1523                N                   1607                N                   19                  N   0      N   0    Y   NA
  Alcohol            N                   19                  N                   20                  N                   368                 N   0      N   6    Y   NA
  Nursing home       N                   138                 N                   0                   N                   0                   N   0      N   0    N   0
  COPD               Y                   NA                  N                   0                   N                   12                  N   0      N   0    N   0
  Asthma             Y                   NA                  Y                   NA                  Y                   NA                  N   0      N   0    Y   NA
  Pleural effusion   N                   123                 N                   0                   N                   107                 N   0      N   0    N   25
  Heart failure      N                   124                 N                   0                   N                   4                   N   0      N   0    N   0
  CAD                Y                   NA                  N                   0                   N                   1                   N   0      Y   NA   N   0
  CVD                N                   123                 N                   0                   N                   1                   N   0      N   0    N   0
  Liver disease      N                   123                 N                   0                   N                   3                   N   0      N   0    N   0
  Renal disease      N                   123                 N                   0                   N                   3                   N   0      N   0    N   0
  Cancer             N                   123                 N                   0                   N                   7                   N   0      N   0    N   0
  Diabetes           Y                   NA                  N                   0                   N                   0                   N   0      Y   NA   N   0
  Dementia           Y                   NA                  N                   0                   N                   5                   N   0      N   0    N   1
  Seizure            Y                   NA                  Y                   NA                  N                   0                   N   0      N   0    N   0
  Confusion          N                   101                 N                   0                   N                   2                   N   0      N   0    N   0
  BUN                N                   127                 N                   0                   N                   787                 N   482    N   0    N   683
  Urea               Y                   NA                  N                   0                   N                   787                 N   485    N   0    N   683
  Resp               N                   8                   N                   0                   N                   482                 N   121    N   0    N   683
  sBP                N                   129                 N                   0                   N                   267                 N   41     N   0    N   9
  dBP                N                   4                   N                   46                  N                   351                 N   50     N   0    N   45
  Temp               Y                   NA                  N                   0                   N                   269                 N   46     N   0    N   33
  HR                 N                   1                   N                   0                   N                   316                 N   14     N   0    N   4
  PaO~2~             N                   123                 N                   60                  N                   1328                N   1137   N   1    N   2608
  pH                 Y                   NA                  N                   58                  N                   1328                N   1167   N   0    N   2608
  Glucose            N                   190                 N                   2                   N                   828                 N   428    N   0    N   691
  Na                 N                   171                 N                   0                   N                   792                 N   143    N   1    N   677
  ICU/vent           Y                   NA                  N                   0                   N                   0                   N   0      N   0    Y   NA
  ICU/any            N                   0                   N                   0                   N                   0                   N   0      N   0    N   9
  HDU                Y                   NA                  N                   0                   Y                   NA                  Y   NA     N   1    Y   NA
  ICU/HDU            N                   0                   N                   0                   N                   0                   N   0      N   0    N   0
  Death              N                   0                   N                   0                   N                   0                   N   0      N   0    N   56

BUN, blood urea nitrogen; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CVD, cerebrovascular disease; dBP, diastolic blood pressure; HDU, high dependency unit; HR, heart rate; ICU, intensive care unit; N, no; NA, not applicable; sBP, systolic blood pressure; Y, yes.
